SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)) by Hiscox, S









Atlas Genet Cytogenet Oncol Haematol. 2010; 14(3)  301 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral 
oncogene homolog (avian)) 
Stephen Hiscox 
Welsh School of Pharmacy, Redwood Building, Cardiff University, Cardiff, UK (SH) 
 
Published in Atlas Database: April 2009 
Online updated version: http://AtlasGeneticsOncology.org/Genes/SRCID448ch20q11.html 
DOI: 10.4267/2042/44715 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: ASV (Avian Sarcoma Virus); SRC1; c-
SRC; p60-Src; pp60c-Src 
HGNC (Hugo): SRC 
Location: 20q11.23 
Note 
The Src kinase proto-oncogene has a high degree of 
similarity to the v-src gene of Rous sarcoma virus, 
although the C-terminal domain of v-Src is trunca-ted 
and lacks the regulatory Tyr527 and therefore is not 
subjected to downregulation by Csk. Src kinase is 
implicated in the regulation of embryonic development, 
cell differentiation and proliferation. Src has been 
suggested to play a key role in cancer, where it may




The gene consists of 14 exons. Two isoforms have been
described differing in their 5' UTRs. Variant 1 
represents the longer transcript although both isoforms 
1 and 2 encode the same protein. 
Description 
Size: 61.33 Kb, 14 exons. mRNA: 4145 bases. 
Protein 
Note 
Src can be phosphorylated on Tyr-530 by CSK (c-Src 
kinase). The phosphorylated form is termed pp60c-src. 
Phosphorylation of this tyrosine allows facilitates 
interaction between the C-terminal tail and the SH2 















Note: This variant (isoform 1) represents the longer Src 
transcript although both isoforms 1 and 2 encode the 
same protein as the difference is in the 5' UTR. 
  
Linear representation of the protein structure of human Src family members, showing the six distinct domains. N and C denote N- and C-
termini respectively. Location of major regulatory phosphorylation sites and the myristolation signal sequence are shown. 
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Description 
Size: 536 amino acids; 59.835 KDa. 
Src is 59.6 KDa in size and has a domain structure 
comprised of six distinct functional regions (see figure 
above). These include an N-terminal SH4 domain that 
contains a lipid-modification sequence allowing 
targeting of Src to cellular membranes, and an adjacent, 
poorly-conserved region thus being unique to each Sr  
family member. SH3 and SH2 domains adjacent to the 
N-terminus facilitate protein-protein interactions 
between Src and its interacting proteins whilst the SH1 
domain allows ATP and substrate binding and has 
tyrosine kinase activity; autophosphorylation of Y419 
within this domain is required for the maximum kinase 
activity of Src. The negative regulatory tail of Src 
contains a tyrosine at 530, the phosphorylation of 
which promotes a conformational change to produce an 
inactive Src molecule. Sequences within the C-
terminus of Src have been recently identified to 
facilitate protein-protein interactions have been shown 
to regulate Src function in addition to its kinase 
activity. 
Expression 
Ubiquitously expressed but with particularly high 
levels in brain tissue, osteoclasts and platelets. 
Localisation 
Predominantly cytoplasmic and/or plasma mem-brane, 
the latter due to myristolation of the N-terminus. 
Activated Src has also been reported in the cell nuc eus 
in some tumour tissues. 
Function 
Src can interact with a diverse array of cellular fctors 
allowing it to regulate a variety of normal and 
oncogenic processes that ultimately result in cell 
proliferation, differentiation, survival, adhe-sion, 
motility, invasion and angiogenesis (Thomas and 
Brugge, 1997; Summy and Gallick, 2003). Such 
interacting partners include receptor tyrosine kinases 
(e.g. the EGF receptor family (Biscardi et al., 1998)), 
integrins (Galliher and Schiemann, 2006; Huveneers t 
al., 2007), cell-cell adhesion molecules (Giehl and 
Menke, 2008), in addition to STATs (Silva, 2004), 
FAK (Brunton and Frame, 2008), the adaptor protein 
p130Cas (Chang et al., 2008) and GPCRs (McGarrigle 
and Huang, 2007). Importantly, Src can also interact 
with the oestrogen receptor (Weatherman, 2008), where 
it has been shown to be pivotal in both non-genomic 
ER activation of signalling pathways and gene 
transcription events. The ability of Src to function as 
both an effector and regulator of receptor-induced 
signalling allows it to mediate cross-talk between 
normally distinct signalling pathways and thus regulate 
a wide variety of both normal and oncogenic processes, 
including proliferation, differentiation, survival, 
adhesion, motility, invasion and angiogenesis. 
Homology 
c-Src is the prototypic member of a family of nine non-
receptor tyrosine kinases which share the same domain 
structure (Src, Fyn, Yes, Lyn, Lck, Hck, Blk, Fgr and 
Frk) (Erpel and Courtneidge, 1995) and are expressed 
in vertebrates. All Src family members have the same 
basic structure of an N-terminal, unique domain 
containing a myristylation site and frequently a 
palmitoylation site; regulatory SH3 and SH2 domains; 
a catalytic domain that has its active site wedged 
between the two lobes of the molecule, and a C-
terminal regulatory tail that contains the hallmark 
regulatory tyrosine residue (Tyr527 in Src). The 
activity of Src family kinases is suppressed upon 
phosphorylation of Tyr527, allowing binding of the C-
terminal domain to the SH2 domain. The SH2 and SH3 
domains bind phosphotyrosine and proline-rich 
peptides, respectively; through these interactions, they 
participate in intra- and intermolecular regulation f 
kinase activity, as well as localization and substrate 
recognition. Differences in the SH2 linker sequences 
within Src family kinases correlate with the division of 
the Src kinase family into two separate subfamilies: 
Group A: Src, Fyn, Yes, Fgr and Group B: Lyn, Hck, 
Lck and Blk. Frk forms a separate but linked subfamily 
but with homologues also found in invertebrates. Src
family members, with the exception of Src, Fyn and 
Yes, exhibit tissue-restricted distribution, being found 
primarily in cells of a haematopoietic nature. Below is 
a table constructed from Src homology analysis 




% identity* % similarity** 
Fyn 75 10 
Yes 73 9 
Fgr 66 11 
Lck 60 17 
Lyn 60 17 
Hck 57 17 
Blk 62 13 
 
*Percent identity between Src and protein; defined as: (Same 
AAs/Length of Protein 1) X100% 
**Percent similarity between Src and protein; defined as: (Sim. 
AAs/Length of Protein 1) X100% 
Mutations 
Somatic 
The SRC family of kinases is rarely mutated in primary 
human tumours, although apparently scarce, a 
truncating and activating mutation in Src (at aa 531) 
has been described for a small subset of advanced-stage 
colorectal cancers (Irby et al., 1999). 
 










Elevated Src expression and/or activity has been 
reported in many different cancer types, where it may 
associate with poor clinical prognosis (Irby and 
Yeatman, 2000). Increased Src kinase activity in cancer 
is likely to arise from the deregulation of Src 
expression and/or activation mechanisms rather than
the presence of activating mutations, since genetic 
mutations of this kind are rarely reported for Src (see 
above). Whereas constitutively activated forms of Src
are transforming, wild-type Src has a relatively low 
transformation potential suggesting that Src may act to 
facilitate intracellular signalling through regulation, 
either directly or indirectly, of other signalling proteins. 
Colorectal cancer 
Disease 
Increased Src activity has been widely described in 
colorectal tumour tissue compared with normal 
epithelia and within colon polyps, particularly those 
displaying a malignant phenotype (DeSeau et al., 1987; 
Cartwright et al., 1994). In colorectal cancer tissue 
studies, elevated Src kinase activity is associated with a 
poor clinical outcome (Aligayer et al., 2002). In vitro 
studies suggest that in colon cancer, Src may contribute 
more to disease spread than to increased proliferation 
(Jones et al., 2002). 
Breast cancer 
Disease 
Src kinase activity is increased in breast cancer tissue 
compared to normal tissues (Verbeek et al., 1996). In 
vivo animal models suggest that Src activity is elevat d 
in breast tumours over-expressing HER2 and 
interaction between Src and erbB family members may
promote the develop-ment of a more aggressive disease 
clinically (Biscardi et al., 2000; Tan et al., 2005). 
Physical interactions between Src and growth factor 
receptors are reported in breast cancer tissues and cells, 
particularly with receptor tyrosine kinases of the EGFR 
family allowing Src to regulate signal-ling pathways 
that may contribute to aggressive breast cancer cell 
behaviour. Src is also intimately involved with Her2 
pathway signalling in breast cancer, the result of which 
is the promotion of an invasive phenotype (Vadlamudi 
et al., 2003; Tan et al., 2005). 
Oestrogenic signalling plays a critical role in promoting 
breast cancer cell growth where ligand-induced 
activation of oestrogen receptors (ERs) results in ge e 
transcription mediated by the ER, in complex with 
various co-activators/co-repressor molecules. In such 
cases, Src is able to potentiate ER-mediated, AF-1 
dependent gene transcription through indirect 
phosphorylation of nuclear ER via ERK1/ERK2 (Feng 
et al., 2001) and Akt (Campbell et al., 2001; Shah et al., 
2005) and through regulation of FAK-p130CAS-JNK 
signalling pathway activity and the subsequent 
activation of co-activator molecules including CBP 
(PAG1) and GRIP1 (NCOA2). Furthermore, Src 
appears to mediate non-genomic ER signalling through 
ERK and Akt pathways (Castoria et al., 2001; Wessler 
et al., 2006) to regulate cellular proliferation and 
survival (Castoria et al., 1999; Migliaccio et al., 2000). 
That Src is involved in both EGFR/Her2 and ER 
signalling has led to Src being implicated in growth 
factor-ER cross talk mechanisms in breast cancer and 
the development of endocrine resistance (Arpino et al., 
2008; Massarweh and Schiff, 2006; Hiscox et al., 2006; 
Hiscox et al., 2009). 
Hematopoietic cancers 
Disease 
The majority of Src family kinases are highly express d 
in cells of a hematopoietic origin where they are 
suggested to regulate growth and prolifera-tion. Src
itself is, along with related family kinase members, are 
implicated in imatinib-resistant, BCR-ABL-expressing 
CML (Li, 2008). 
Other tumour types 
Disease 
Src protein and activity have been identified as being 
increased in a number of other tumour types including 
gastric, pancreatic, lung and ovarian tumours compared 
to normal tissue suggesting a possible role for Src in 
these tumours. 
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